[Dasatinib-induced follicular lymphoid hyperplasia, an entity to know]

Ann Pathol. 2023 Jan;43(1):45-51. doi: 10.1016/j.annpat.2022.09.005. Epub 2022 Oct 17.
[Article in French]

Abstract

Follicular lymphoid hyperplasia induced by dasatinib is an entity recently described. It is sometimes difficult to rule out the diagnostic of small B-cell lymphoma. Usually, the node is swollen, with follicular architecture conserved, composed by germinal centers with variable size and shape, with a hight number of mitoses and tingible bodies macrophages inside. Follicular lymphoid hyperplasia is isolated or associated with multiple reactive patterns. The immunohistochemical profil of germinal centers is CD20+, CD10+, BCL6+, BCL2-. Swollen node disappears in a short time after dasatinib discontinuation. Clinicians and pathologists need to be aware of this entity, so as not to avoid mistakenly suspect lymphoma when lymphadenopathy occurs in a patient with chronic myeloid leukemia treated with dasatinib.

Keywords: Dasatinib; Drug induced lymphadenopathy; Follicular lymphoid hyperplasia; Hyperplasie folliculaire lymphoïde; Lymphadénopathie médicamenteuse; Side effects.

Publication types

  • English Abstract

MeSH terms

  • Dasatinib / adverse effects
  • Humans
  • Hyperplasia / chemically induced
  • Leukemia, Lymphocytic, Chronic, B-Cell*
  • Lymphadenopathy*
  • Lymphoma, Follicular* / diagnosis

Substances

  • Dasatinib